Bill & Melinda Gates Foundation10 Jun 2020 07:56
You never know who might be watching and waiting on SNGs results, food for thought
Fujifilm Holdings Corp will spend $928 million to double capacity at a drug manufacturing facility in Denmark, which it has pledged to use in producing Covid-19 treatments, as the Japanese company steps up its pivot towards healthcare, Reuters reports.
The investment in Fujifilm Diosynth Biotechnologies will expand production lines for bulk drug substances and cultivate cells for producing viral vaccines, Fujifilm announced on Tuesday. It bought the facility in Hillerod, Denmark, in August from Biogen Inc for about $890 million.
Fujifilm previously announced that the Denmark site would offer future manufacturing capacity to the Covid-19 Therapeutics Accelerator to speed-up the response to the global pandemic.
It is an initiative launched by the Bill & Melinda Gates Foundation and two other large charities, aimed at accelerating drug development and identifying a promising Covid-19 therapeutic candidate based on efficacy and safety data demonstrated in clinical trials. Fujifilm’s pharma arm is testing its own anti-flu drug Avigan as a treatment for Covid-19.